Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Are natural killer cells the key to treating Epstein-Barr virus-associated lymphoproliferative disorders?

Hepatitis C virus infection can affect lymphoproliferative disorders only as a cofactor for Epstein-Barr virus in liver transplant recipients: PTLD.Int survey.

OBJECTIVES Hepatitis C virus infection has a 10.5% frequency in liver transplant posttransplant lymphoproliferative disorders. Studies have suggested that hepatitis C virus infection plays a role in developing posttransplant lymphoproliferative disorders. Pooling data of posttransplant lymphoproliferative disorders developing in liver recipients from the literature, we analyzed and compared cha...

Favorable outcome of Epstein-Barr virus-associated B-cell lymphoproliferative disorder complicated by immunoglobulin G4-related disease treated with rituximab-based therapy: a case report

BACKGROUND After acute infection of Epstein-Barr virus, Epstein-Barr virus-infected B cells survive but usually do not show clonal proliferation. However, Epstein-Barr virus-infected B cells occasionally acquire a proliferative capacity that provokes clonal lymphoproliferative disorders. We herein present a case with Epstein-Barr virus-infected CD30+ B cell and immunoglobulin G4+ plasmacytoid c...

Pretransplant Epstein-Barr virus serostatus and incidence of posttransplant lymphoproliferative disorder in pediatric renal transplants.

OBJECTIVES Pediatric renal transplant recipients are at increased risk of Epstein-Barr virus infection which may be due to the high percentage of Epstein-Barr virus seronegative recipients at the time of transplant in the pediatric age group. We aimed to assess the Epstein-Barr virus serostatus of recipients and donors and the incidence of posttransplant lymphoproliferative disorder in pediatri...

Epstein-Barr virus infection and lymphoproliferative disorder after hematopoietic cell transplantation.

Common herpes viruses such as Epstein-Barr virus (EBV) cause infection and disease after hematopoietic cell transplantation (HCT). Post-transplantation lymphoproliferative disorder following allogeneic HCT is a rare but life-threatening disease, mostly associated with EBV-infected B cells. Anti-CD20 monoclonal antibodies (e.g., rituximab) target normal and infected B cells and further suppress ...